---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-052068"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:11:49.762568+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InfuSystem TTM revenue $141.1M, AEBITDA $30.2M; guides 6-8% FY2025 growth

## Summary
- TTM revenue through Sep 30, 2025: $141.1M; estimated 2025 revenue grows 6-8% over 2024's $134.9M.
- Adjusted EBITDA TTM $30.2M (21.4% margin); estimated 2025 AEBITDA margin >20% of revenue.
- Patient Services net revenue TTM $85.4M; Device Solutions $55.7M; gross margin 55.4%.
- Stock repurchases of $9.7M under $20M program through Sep 30, 2025; program expires Jun 30, 2026.
- ERP upgrade investment estimated $2.6M in 2025 ($3.3M cumulative); expected completion Q1 2026.

## SEC filing metadata
- accession: 0001628280-25-052068
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828025052068/0001628280-25-052068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828025052068/infu-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-052068
- JSON: https://secwatch.observer/filing/0001628280-25-052068.json
- Plain text: https://secwatch.observer/filing/0001628280-25-052068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.